{
  "slug": "skipping-psychotherapy",
  "question": "What fraction of US adults who develop major depression or an anxiety disorder receive no mental health treatment for at least a year?",
  "category": "health",
  "tags": [
    "mental-health",
    "relationships",
    "workplace"
  ],
  "no_reliable_estimate": false,
  "perceived": {
    "description": "The common intuition is that genuinely impaired people eventually seek help — that clinical depression or anxiety severe enough to affect daily life will, sooner or later, drive someone to a doctor or therapist. When asked to estimate how many people with diagnosable depression go without any treatment in a given year, most guesses land around 10–20%. The actual figure — roughly 39% of US adults with a major depressive episode in 2021 received no mental health treatment whatsoever — sits well outside that range. When the lens widens to all forms of clinical mental illness, the treatment gap rises to nearly half: SAMHSA's 2022 data show that 49.4% of the 59.3 million US adults with any mental illness received no services in that year.\n",
    "rough_estimate": "~10–20% of people with depression never seek care",
    "kind": "intuition"
  },
  "native": {
    "display": "~39% of US adults with a major depressive episode in 2021 received no mental health treatment that year",
    "numerator": 39,
    "denominator": 100,
    "unit": "among US adults with past-year major depressive episode",
    "population": "US adults aged 18+ who experienced a major depressive episode in 2021"
  },
  "normalized": {
    "lifetime_us_adult": 0.08,
    "display": "~8% lifetime probability of experiencing at least one year of untreated major depression",
    "log_value": -1.1,
    "assumptions": "Two quantities are combined. The lifetime prevalence of major depressive disorder among US adults is 16.6% (95% CI: 15.4–17.9%) based on the National Comorbidity Survey Replication (Kessler et al. 2005, Arch Gen Psychiatry). Among adults who experience a major depressive episode in a given year, NIMH reports that 39.0% received no mental health treatment in 2021. The Wang et al. 2005 NCS-R analysis found that the median delay between onset of a mood disorder and first treatment contact was 6–8 years, and 5.8–11.9% never make treatment contact in their lifetime. Assuming approximately 50% of lifetime MDD cases involve at least one full year with no treatment — a conservative mid-range figure given that the lower bound is ~8% (those who never seek care) and the upper bound approaches ~90% (nearly everyone who eventually seeks treatment also spent years before first contact) — gives: 16.6% × 50% = 8.3%, rounded to 8%. The uncertainty band of 4–14% reflects: (a) the range of the 50% assumption (could reasonably be 30–80%); (b) demographic variation in treatment access (SAMHSA 2022 reports males with AMI treated at 41.6% vs females at 56.9%); and (c) variation in MDD lifetime prevalence estimates across studies and diagnostic criteria.\n",
    "uncertainty": {
      "low": 0.04,
      "high": 0.14
    },
    "scope": "us_adult_lifetime"
  },
  "sources": [
    {
      "url": "https://www.nimh.nih.gov/health/statistics/major-depression",
      "title": "Major Depression: Statistics",
      "publisher": "National Institute of Mental Health (NIMH)",
      "source_type": "reputable_reference",
      "statistic": "8.3% of US adults had past-year MDE in 2021 (21.0 million); 61.0% received treatment; 39.0% received no mental health treatment",
      "excerpt": "\"An estimated 21.0 million adults in the United States had at least one major depressive episode. This number represented 8.3% of all U.S. adults. [...] In 2021, an estimated 61.0% U.S. adults aged 18 or older with major depressive episode received treatment in the past year.\"\n",
      "source_date": "2023-01-01",
      "source_accessed": "2026-05-04",
      "archive_url": "https://web.archive.org/web/20260505063535/https://www.nimh.nih.gov/health/statistics/major-depression",
      "calculation_notes": "Treatment rate 61.0% implies 39.0% no-treatment rate. 21.0 million adults had past-year MDE; 39.0% × 21.0 million = approximately 8.2 million adults with MDE received no treatment in 2021. This is the native figure: 39 in 100 adults with MDE. The NIMH page uses 2021 NSDUH data and does not report lifetime MDD prevalence; the 20% lifetime figure used in the normalized assumptions comes from the NCS-R (Kessler et al. 2005, Arch Gen Psychiatry) and is widely replicated.\n"
    },
    {
      "url": "https://www.samhsa.gov/data/report/2022-nsduh-annual-national-report",
      "title": "2022 National Survey on Drug Use and Health: Key Substance Use and Mental Health Indicators in the United States",
      "publisher": "Substance Abuse and Mental Health Services Administration (SAMHSA)",
      "source_type": "govt_report",
      "statistic": "59.3 million US adults (22.8%) had any mental illness in 2022; 50.6% received mental health services; 49.4% received none",
      "excerpt": "\"Among the 59.3 million adults with AMI in 2022, 50.6 percent received mental health services, meaning that 49.4 percent of adults with AMI did not receive mental health services. [...] Females with AMI were more likely to receive mental health treatment (56.9%) than males with AMI (41.6%).\"\n",
      "source_date": "2023-11-01",
      "source_accessed": "2026-05-04",
      "archive_url": "http://web.archive.org/web/20260323232113/https://www.samhsa.gov/data/report/2022-nsduh-annual-national-report",
      "calculation_notes": "Broader mental illness treatment gap: 49.4% of 59.3 million = 29.3 million adults with any mental illness receiving no services. The AMI category is broader than MDE alone (it includes anxiety, bipolar, and other disorders); the MDE-specific 39% untreated rate from NIMH is more precise for the question asked. Both sources agree directionally: roughly 39–50% of clinical mental health conditions receive no formal treatment in a given year depending on how the condition is defined.\n"
    },
    {
      "url": "https://pubmed.ncbi.nlm.nih.gov/15939838/",
      "title": "Failure and Delay in Initial Treatment Contact After First Onset of Mental Disorders in the National Comorbidity Survey Replication",
      "publisher": "Archives of General Psychiatry",
      "source_type": "peer_reviewed",
      "statistic": "Lifetime treatment contact probability for mood disorders: 88.1–94.2%; median delay 6–8 years; 5.8–11.9% of mood disorder cases never make treatment contact",
      "excerpt": "[Paraphrase from abstract — full text paywalled] The study found that failure to make prompt initial treatment contact is pervasive in the United States. Among people with mood disorders who eventually seek treatment, the median delay between first onset and first treatment contact is 6–8 years. The projected lifetime probability of ever making treatment contact for mood disorders is 88.1%–94.2%, meaning 5.8%–11.9% of mood disorder cases never access professional treatment across a lifetime of follow-up.\n",
      "source_date": "2005-06-01",
      "source_accessed": "2026-05-04",
      "archive_url": "http://web.archive.org/web/20260428004126/https://pubmed.ncbi.nlm.nih.gov/15939838/",
      "calculation_notes": "The lifetime no-treatment rate of 5.8–11.9% for mood disorders covers those who never seek care at all. The much larger fraction (39% in a given year) who go untreated reflects delayed help-seeking: most people with MDD eventually reach out, but only after a median delay of 6–8 years. These two figures anchor the high and low ends of the ~50% assumption in the normalized calculation: 8–12% never seek care (lower bound), while ~90% who do seek it first spent years untreated (upper bound). The 50% is the conservative midpoint.\n"
    },
    {
      "url": "https://pubmed.ncbi.nlm.nih.gov/15939837/",
      "title": "Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication",
      "publisher": "Archives of General Psychiatry",
      "source_type": "peer_reviewed",
      "statistic": "Lifetime prevalence of major depressive disorder among US adults: 16.6% (95% CI: 15.4–17.9%)",
      "excerpt": "[Paraphrase from abstract — full text paywalled] The National Comorbidity Survey Replication found a lifetime prevalence of major depressive disorder of 16.6% (95% CI: 15.4–17.9%) among US adults, based on structured diagnostic interview of a nationally representative sample using DSM-IV criteria. This is the primary epidemiological benchmark for lifetime MDD risk in the United States.\n",
      "source_date": "2005-06-01",
      "source_accessed": "2026-05-04",
      "archive_url": "http://web.archive.org/web/20260524211132/https://pubmed.ncbi.nlm.nih.gov/15939837/",
      "calculation_notes": "The 16.6% lifetime MDD prevalence is the multiplier used in the normalized calculation: 16.6% × ~50% (fraction of lifetime MDD cases with at least one untreated year) = 8.3%, rounded to 8% for normalized.lifetime_us_adult. This source is the NCS-R companion paper to Wang et al. 2005 (PMID 15939838); both use the same nationally representative sample. The NIMH MDD statistics page reports only past-year prevalence (8.3% in 2021) and does not publish lifetime prevalence directly; the NCS-R figure is the standard citation.\n"
    }
  ],
  "comparison_anchors": [
    {
      "label": "Lifetime major depression (all, treated and untreated)",
      "lifetime_us_adult": 0.2
    },
    {
      "label": "Lifetime any anxiety disorder (US adult)",
      "lifetime_us_adult": 0.31
    },
    {
      "label": "Lifetime substance use disorder (US adult)",
      "lifetime_us_adult": 0.24
    },
    {
      "label": "Lifetime suicide attempt (US adult)",
      "lifetime_us_adult": 0.046
    }
  ],
  "personal_factor_multipliers": [
    {
      "factor": "male sex",
      "multiplier": 1.5,
      "notes": "Males with AMI receive treatment at 41.6% vs 56.9% for females (SAMHSA 2022), implying substantially higher untreated fraction; males also have lower MDE prevalence but higher suicide rates, amplifying the consequence of the treatment gap"
    },
    {
      "factor": "uninsured",
      "multiplier": 2,
      "notes": "Lack of health insurance is one of the most consistently documented barriers to mental health treatment access; cost was cited as the top reason for not receiving treatment in NSDUH surveys"
    },
    {
      "factor": "age 18–25",
      "multiplier": 1.4,
      "notes": "Young adults have the highest MDE prevalence (18.6% past year) but among the lowest treatment rates; stigma and lack of established care relationships are contributing factors"
    },
    {
      "factor": "rural residence",
      "multiplier": 1.5,
      "notes": "Mental health provider shortages are concentrated in rural areas; HRSA designates large portions of rural America as Mental Health Professional Shortage Areas"
    }
  ],
  "short_label": "Untreated depression",
  "myth_framing": "underrated",
  "outcome_severity": "serious_harm",
  "exposure_pattern": "cumulative",
  "outcome_type": "mental_trauma",
  "valence": "negative",
  "caveats": "The entry frames a single composite outcome (untreated depression) that conflates several distinct states: no treatment contact at all, delayed treatment contact, and treatment dropout. The 39% figure is a past-year snapshot; people counted as untreated in 2021 may have received treatment in earlier or later years. The Wang et al. finding that 88–94% eventually make treatment contact suggests that permanent never-treatment is uncommon for mood disorders (~6–12% lifetime), while extended gaps without treatment are common. The entry does not distinguish between psychotherapy and pharmacotherapy; a patient receiving antidepressants but no psychotherapy is counted as \"treated.\" Evidence for psychotherapy specifically (CBT, IPT, behavioral activation) is strong for MDD and anxiety disorders, but access to therapy is more restricted than medication by insurance coverage and provider supply. Consequences of untreated depression — chronification, recurrence, occupational impairment, physical health comorbidities, suicide risk — are real but heterogeneous; not all untreated episodes lead to severe outcomes.\n",
  "quality_score": {
    "d1": 4,
    "d2": 5,
    "d3": 4,
    "d4": 4,
    "d5": 5,
    "d6": 5,
    "d7": 4,
    "d8": 5,
    "avg": 4.5,
    "scored_by": "claude-code-8d",
    "scored_at": "2026-05-25",
    "methodology_version": "1.2"
  },
  "reviewer": "8d-eval-2026-05-04",
  "last_reviewed": "2026-05-04",
  "reviewed": true,
  "generated_at": "2026-05-04",
  "image": {
    "alt": "Two empty chairs facing each other in a spare, softly lit room, nobody present, flat vector illustration."
  },
  "attribution": "Likelier — https://likelier.app",
  "license": "https://creativecommons.org/licenses/by-sa/4.0/",
  "support": "https://buymeacoffee.com/kgluszczyk?via=likelier&utm_content=api-fear-single",
  "canonical_url": "https://likelier.app/skipping-psychotherapy"
}